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Abstract
Recent changes in the management of patients with haematological malignancies might have inﬂuenced the aetiology, characteristics,
antimicrobial resistance and outcomes of bloodstream infection (BSI) during neutropenia. We compared 272 episodes of BSI in adult
neutropenic patients with cancer prospectively collected from January 1991 to December 1996 (ﬁrst period), when quinolone prophy-
laxis was used, with 283 episodes recorded from January 2006 to March 2010 (second period), when antibacterial prophylaxis was
stopped. Patients in the second period were signiﬁcantly older and were more likely to have graft-versus-host disease and a urinary
catheter in place, whereas the presence of a central venous catheter, parenteral nutrition, corticosteroids and antifungal and quinolone
prophylaxis, were more frequent in the ﬁrst period. More patients in the ﬁrst period had mucositis and soft-tissue infection as the ori-
gin of BSI, but an endogenous source was more common during the second. Gram-positive BSI was more frequent in the ﬁrst period
(64% versus 41%; p <0.001), mainly due to coagulase-negative staphylococci and viridans group streptococci. In the second period
gram-negative BSI increased (28% versus 49%; p <0.001), quinolone susceptibilities were recovered, but multidrug-resistant gram-nega-
tive BSI also increased (1% versus 6%; p <0.001). Although patients in the second period were more likely to need admission to the
intensive-care unit, overall case-fatality rate was similar in the two periods (19% versus 15%). The aetiology of BSI in neutropenic
patients with cancer has shifted from gram-positive to gram-negative organisms. Multidrug resistance among gram-negative bacilli is
emerging as a therapeutic challenge. Overall case-fatality rate remains high.
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Introduction
As early as the 1960s, the importance of severe gram-nega-
tive bloodstream infection (BSI) during intensive chemother-
apy for acute myeloid leukaemia was recognized [1].
Throughout the 1960s and 1970s, gram-negative bacilli
(GNB) were the most frequent causative agents of BSI in
patients with cancer who are neutropenic [2]. During the
next two decades, the causes of BSI shifted dramatically from
GNB to gram-positive cocci, especially viridans group strep-
tococci (VGS) and coagulase-negative staphylococci [3–5].
Importantly, about 11% of episodes of VGS bacteraemia
presented with serious clinical complications such as septic
shock and adult respiratory distress syndrome, leading to sig-
niﬁcant mortality [6]. Streptococcus mitis was most frequently
the species causing these infections [6]. In addition, some of
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these strains were resistant to penicillin and presented
diminished susceptibility to other b-lactams, particularly ceft-
azidime [3,6–8].
Some of the factors associated with the shift towards
more gram-positive infecting organisms included oral mucosi-
tis as a result of the increasing use of certain chemothera-
peutic drugs, such as cytosine arabinoside, profound and
prolonged neutropenia, increasing use of central venous
catheters, trimethoprim–sulfamethoxazole and ﬂuoroquino-
lone prophylaxis and use of antacids and histamine 2 block-
ers [9,10].
Changes in the general management of patients with hae-
matological malignancies are still ongoing, with the introduc-
tion of newer types of myeloablative chemotherapy and
transplants, newer immunosuppressive agents, and changes in
the antibacterial and antifungal prophylaxis. These changes
may have inﬂuenced the characteristics of BSI during neutro-
penia, which remains a major cause of mortality in this
patient population. Data regarding the impact of these
changes in the aetiology, characteristics, changes in antimi-
crobial resistance and outcomes of BSI in neutropenic
patients with cancer are limited. We designed a prospective
study in which we compared our current data with data
from another prospective study from an earlier time period
carried out at the same institution.
Design and Methods
Setting, patients and study design
We conducted a prospective observational study at a 200-
bed university referral cancer centre in Barcelona, Spain.
From January 2006 to March 2010 all episodes of BSI occur-
ring in hospitalized neutropenic adult patients with haemato-
logical malignancies and undergoing haematopoietic stem cell
transplant were included. Information on baseline character-
istics, clinical features, antimicrobial resistance and outcome
was recorded in a speciﬁc database. These episodes (labelled
as the ‘second period’) were compared with those prospec-
tively collected from January 1991 to December 1996 at the
same institution (labelled as the ‘ﬁrst period’). Information
regarding some of the episodes from the ﬁrst period has
been previously described [11].
Since the beginning of the 1990s, all the positive results of
blood cultures are reported daily from the Microbiology Lab-
oratory to an infectious disease physician. All cases are
revised and followed up, and changes in antimicrobial treat-
ment are advised when necessary. Information regarding
these episodes are prospectively collected and recorded in a
speciﬁc database.
Whereas prophylaxis with oral norﬂoxacin (400 mg twice
daily) was given in patients with neutropenia in the ﬁrst per-
iod, no universal antibacterial prophylaxis was given in the
second period. Empirical antibiotic therapy for febrile neu-
tropenia in the ﬁrst period was mainly ceftazidime (or imipe-
nem) plus amikacin, whereas cefepime (or imipenem) plus
amikacin were used in the second. The study was approved
by the ethics committee of our institution.
Deﬁnitions
Neutropenia was deﬁned as an absolute neutrophil count
<500/mm3. Quinolone prophylaxis was considered to be pres-
ent when a quinolone was administered for at least 3 days
before the onset of BSI. Prophylactic antifungal treatment was
considered when a systemic antifungal agent was administered
for at least 3 days before the onset of BSI. Severe mucositis
was deﬁned as the presence of multiple ulcerations covering
more than 25% of the oral mucosa. A BSI caused by coagulase-
negative staphylococci and other potential skin contaminants
was considered to be signiﬁcant when they grew in at least
two blood cultures or in one blood culture and in one other
site. Corticosteroid therapy was recorded when a patient was
receiving corticosteroids at the time of the episode of BSI or
in the previous month. The BSI was considered to be from an
unknown or endogenous source in patients in whom no other
sources were identiﬁed. Shock was deﬁned as a systolic pres-
sure <90 mmHg that was unresponsive to ﬂuid treatment or
required vasoactive drug therapy [6]. The VGS were consid-
ered to be resistant to penicillin when the MIC was ‡0.25 mg/
L, and Escherichia coli was considered to be resistant to quinol-
ones when the MIC was ‡2 mg/L [12]. The GNB were consid-
ered to be multidrug-resistant as follows: (i) extended
spectrum b-lactamase-producing (ESBL) Enterobacteriaceae,
(ii) AmpC cephalosporinase hyperproducing Entero-
bacteriaceae, (iii) microorganisms with intrinsic resistance
mechanisms, such as Stenotrophomonas maltophilia, (iv) multi-
drug-resistant strains including Pseudomonas aeruginosa and
Acinetobacter baumannii. Multidrug-resistant strains were
deﬁned as those resistant to at least three classes of antibiotics:
carbapenems, ureidopenicillins, cephalosporins (ceftazidime
and cefepime), monobactams, aminoglycosides and ﬂuorquinol-
ones [13]. Early case-fatality rate was deﬁned as death within
48 h of the onset of BSI. Overall case-fatality rate was deﬁned
as death by any cause within the ﬁrst 30 days of onset.
Microbiological studies
During the ﬁrst period, blood samples were processed by
Bactec NR-860 (Becton Dickinson Diagnostic Systems,
Sparks, MD, USA), and in the second period, by Bactec 9240
(Becton-Dickinson Microbiology Systems Sparks, MD, USA).
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In both periods, the inoculated bottles were incubated for
5 days at 35C before being discharged. The GNB and
Enterococcus spp. were identiﬁed and their antibiotic suscepti-
bility was tested using commercial panels from the Micro-
Scan system (Siemens Healthcare Diagnostics Inc, West
Sacramento, CA, USA). Gram-positive bacteria, including
VGS and coagulase-negative staphylococci, and the other
microorganisms were identiﬁed using standard methods that
are described elsewhere [14]. Antibiotic susceptibility in VGS
was performed by a microdilution method in accordance
with CLSI guidelines [15]. In gram-positive bacteria, the anti-
biotic susceptibility was determined by the disc diffusion
method, in accordance with CLSI recommendations [16].
Resistance breakpoints were deﬁned according to CLSI crite-
ria [12].
Statistical analysis
Continuous variables were compared by the Mann–Whitney
U test and the Student’s t test. Qualitative variables were
compared by chi-square test. A p value of <0.05 was consid-
ered statistically signiﬁcant. The analysis was performed with
the stepwise logistic-regression model of the SPSS software
package version 15.0 (SPSS Inc., Chicago, IL, USA).
Results
In total, 283 episodes occurring in 229 patients from the sec-
ond period were compared with 272 episodes in 196 patients
from the ﬁrst period. The incidence of overall bacteraemia (5.6
episodes/1000 hospital stays versus 8 episodes/1000 hospital
stays, OR 1.4 95% CI 1.19–1.66; p <0.001) and gram-negative
bacteraemia (1.5 episodes/1000 hospital stays versus 3.8 epi-
sodes/1000 hospital stays, OR 2.48 95% CI 1.8–3.2; p <0.001)
increased in the second period. Epidemiological and clinical
characteristics of the patients according to the study periods
are shown in Table 1. Patients in the second period were older,
and were more likely to have graft-versus-host disease and a
urinary catheter in place. The presence of a central venous
catheter, parenteral nutrition, severe mucositis, the use of cor-
ticosteroids, and the use of antifungal and quinolone prophy-
laxis, were more frequent in the ﬁrst period. More patients in
the ﬁrst period had severe mucositis and skin and soft-tissue
infection as the source of BSI, whereas an unknown/endoge-
nous source was more common in the second.
Table 2 shows the causative organisms of all episodes of
BSI compared by study periods. Gram-positive BSI was more
common in the ﬁrst period, mostly caused by coagulase-neg-
ative staphylococci and VGS. Gram-negative BSI was more
frequent in the second period, with a higher rate of Entero-
bacteriaceae (other than E. coli), and a higher rate of multi-
drug resistance among GNB. The multidrug-resistant GNB
isolated in the ﬁrst period included A. baumannii in one
patient, and ESBL-E. coli in one patient. In the second period,
the multidrug-resistant GNB isolated were: ESBL-E. coli in
eight patients, multidrug-resistant P. aeruginosa in three,
S. maltophilia in two, and AmpC cephalosporinase hyper-
producing Enterobacter cloacae, ESBL-Klebsiella pneumoniae
and A. baumannii in one patient each.
Antimicrobial susceptibility testing showed a higher rate of
quinolone resistance among all E. coli strains isolated in the
ﬁrst period (71% versus 37%; p <0.001), when quinolone
prophylaxis was used. Penicillin resistance among VGS
remained stable over time (31% versus 32%; p 1.00).
TABLE 1. Epidemiological and clinical characteristics of all
episodes of bacteraemia compared by study periods
First period
n = 272 (%)
Second period
n = 283 (%) p
Male sex 173 (61) 110 (39) 0.59
Age (years, median, range) 49.5 (17–81) 56 (19–89) <0.001
HSCTa 47 (17) 61 (22) 0.23
Type of HSCT
Allogeneic 16 (37) 27 (44)
Autologous 28 (64) 26 (43)
Cord 0 8 (13)
Conditioning regimen
Myeloablative 44 (100) 40 (67) <0.001
Reduced intensity 0 20 (33)
Graft-versus-host disease 0 6 (2) 0.033
Quinolone prophylaxis 150 (56) 1 (0.4) <0.001
Antifungal prophylaxisb 159 (70) 166 (59) 0.01
Previous antineoplastic
chemotherapy (within 1 month)
249 (91.5) 250 (88) 0.25
Current corticosteroid therapy 107 (41) 83 (29) 0.004
Urinary catheter 5 (2) 25 (9) <0.001
Central venous catheter 217 (80) 193 (68) 0.002
Severe mucositis (grade III–IV) 46 (18) 27 (9) 0.004
Parenteral nutrition 39 (14) 8 (3) <0.001
Clinical features at onset
Fever >38C 271 (100) 251 (90) <0.001
Hypotension (<90 mmHg) 18 (7) 21 (26) <0.001
Shock 17 (6) 29 (10) 0.12
Empirical antibiotic therapy
b-lactam + b-lactam 0 12 (4) <0.001
Carbapenem 49 (20) 60 (22) 0.59
Oxyimino-b-lactam 163 (65.5) 160 (58) 0.089
Ceftazidime 162 4 –
Cefepime 0 149 –
Aztreonam 1 7 –
Aminoglycosidec 181 (73) 167 (61) 0.004
Glycopeptide 79 (32) 69 (25) 0.09
Quinolone 1 (0.4) 2 (0.7) 1
Source of bacteraemia
Mucositis 38 (14) 18 (6) 0.003
Unknown/endogenous source 104 (38) 162 (57) <0.001
Respiratory tract 16 (6) 11 (4) 0.32
Urinary tract 3 (1) 8 (3) 0.22
Catheter-related 77 (28) 62 (22) 0.082
Gastrointestinal tract 12 (4) 14 (5) 0.82
Skin and soft tissue infection 12 (4) 2 (1) 0.006
Perianal infection 6 (2) 2 (1) 0.16
Endocarditis 4 (1.5) 1 (0.4) 0.2
Disseminated infection 1 (0.4) 2 (1) 1
aHSCT, haematopoietic stem cell transplant.
bAntifungal prophylaxis in the ﬁrst period was: nystatin 134 patients, ﬂuconazole
32, itraconazole 7, other 17. In the second period: posaconazole 101 patients,
itraconazole 27, ﬂuconazole 17, voriconazole 13, other 8.
cThe aminoglycoside was usually stopped in 48 h, following the infectious dis-
ease physician’s advice.
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Outcomes of all episodes of BSI compared by periods are
shown in Table 3. Intensive-care unit admission and mechani-
cal ventilation were more frequent in the second period.
Early case-fatality rate was also more frequent in the second
period, although the difference did not reach signiﬁcance.
Overall case-fatality rate was similar in the two groups.
Discussion
Since the early 1960s, when the importance of gram-negative
BSI among neutropenic patients with cancer was ﬁrst identi-
ﬁed, the aetiology of BSI in this patient population became
predominantly gram-positive as the result of several changes
in the management of these patients [3–5]. We observed a
new shift towards GNB bacteraemia in neutropenic patients
with cancer in recent years, compared with a previous time
period. This ﬁnding may be attributed in part to the different
epidemiological and clinical characteristics of patients in the
two periods.
Currently, patients undergoing ablative chemotherapy and
transplant for haematological malignancies are older than in
previous years, and new less toxic ablative chemotherapy
regimens and new types of transplants are frequently used.
As a result, we found that patients in the second period
were older and more frequently had graft-versus-host dis-
ease.
On the other hand, the use of antifungal prophylaxis and
antibacterial prophylaxis with quinolones was more common
in the ﬁrst period. Quinolone prophylaxis has been widely
used in neutropenic patients with cancer to decrease the risk
of gram-negative bacteraemia [17,18]. However, it has been
associated with an increased risk of selection of resistant
strains in the gastrointestinal tract [19–22]. The emergence
of faecal quinolone-resistant E. coli colonization and bactera-
emia in neutropenic patients with cancer receiving norﬂoxa-
cin prophylaxis was observed several years ago [19,20],
leading to the discontinuation of this practice in our centre
and at other institutions as well. This change in policy may
be responsible for the reappearance of GNB as the leading
cause of BSI in neutropenic patients with cancer in our cen-
tre, and one might consider reintroducing the prophylaxis.
However, several drawbacks limit the use of quinolone pro-
phylaxis. First, the rate of quinolone resistance among GNB
in our geographical area is high [23]. Second, quinolone use
has been identiﬁed as a risk factor for colonization and infec-
tion by several multidrug-resistant microorganisms, such as
ESBL-E. coli and methicillin-resistant Staphylococcus aureus
[24,25]. And ﬁnally, it has also been associated with the
emergence of a highly virulent Clostridium difﬁcile strain in
several parts of the world [26].
We also found a decrease in gram-positive BSI over time.
Some factors that may have contributed to this decrease are
the reduction in the use of a central venous catheter and
reduced presence of severe mucositis. The use of a central
venous catheter is associated with an increased risk of cathe-
ter-related bacteraemia, and so with coagulase-negative
staphylococci bacteraemia [27], while severe mucositis is
associated with an increased risk of VGS bacteraemia [9–
11,28]. VGS are especially prevalent in the oral cavity, and so
the current use of more speciﬁc agents with less cytotoxic
potential and less mucosal toxicity may reduce the infections
TABLE 2. Causative organisms of all episodes of bactera-
emia compared by study periods
Causative organisms
First period
n = 272 (%)
Second period
n = 283 (%) p
Gram-positive bacteria 174 (64) 116 (41) <0.001
Staphylococcus aureus 10 (6) 14 (12) –
Methicillin-resistant S. aureus 1 (17)a 4 (28.6)a –
Coagulase-negative staphylococci 81 (46.5) 50 (43) –
Corynebacterium spp. 8 (5) 4 (3) –
Viridans group streptococci 71 (42) 22 (23) –
Streptococcus pneumoniae 6 (3) 7 (6) –
Enterococcus spp. 10 (6) 26 (23) –
E. faecalis 3 (30)b 10 (38.5)b –
E. faecium 6 (60)b 13 (50)b –
E. gallinarum 1 (10)b 3 (11.5)b –
Gram-negative bacteria 75 (28) 138 (49) <0.001
Escherichia coli 50 (67) 71 (51) –
Pseudomonas aeruginosa 20 (27) 32 (23) –
Klebsiella pneumoniae 5 (7) 31 (22) –
Klebsiella oxytoca 0 1 (1) –
Proteus mirabilis 0 3 (2) –
Enterobacter cloacae 6 (7) 12 (9) –
Acinetobacter baumannii 1 (1) 2 (1) –
Stenotrophomonas maltophilia 0 2 (1) –
Multi-drug resistant
gram-negative bacillic
2 (3) 16 (11) 0.04
Anaerobes 5 (2) 8 (3) 0.57
Prevotella spp. 3 0 –
Fusobacterium spp. 2 (40) 4 (50) –
Bacteroides spp. 0 2 –
Clostridium spp. 1 2
Fungi 4 (1.5) 12 (4) 0.074
Candida tropicalis 3 7 –
Candida glabrata 0 4 –
Candida krusei 2 0 –
Candida parapsilosis 1 0 –
Fusarium solani 0 1 –
Polymicrobial bacteraemiad 35 (13) 26 (9) 0.17
aPercentage of methicillin-resistant S. aureus among all S. aureus isolates.
bPercentage of different Enterococcus spp. among all enterococcal isolates.
cMultidrug-resistant gram-negative bacilli: extended spectrum b-lactamase-
producing Enterobacteriaceae, AmpC cephalosporinase hyperproducing Enterobac-
teriaceae, multi-drug resistant P. aeruginosa, S. maltophilia, and A. baumannii.
dPolymicrobial bacteraemia was deﬁned as a bloodstream infection caused by at
least two different microorganisms.
TABLE 3. Outcomes of all episodes of bacteraemia com-
pared by study periods
Characteristic
First period
n = 272 (%)
Second period
n = 283 (%) p
Intensive-care unit admission 7 (3) 32 (11) <0.001
Mechanical ventilation 4 (2) 15 (6) 0.018
Early case-fatality rate (48 h) 5 (2) 13 (5) 0.071
Overall case-fatality rate (30 days) 50 (19) 41 (15) 0.25
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caused by VGS. Another plausible explanation is the absence
of quinolone prophylaxis, which has been previously identi-
ﬁed as a risk factor for VGS bacteraemia [9,28]. Similarly, we
also observed that severe mucositis and skin and soft-tissue
infections were the most common sources of BSI in the ﬁrst
period, whereas an unknown/endogenous source was more
frequent in the second period.
Interestingly, penicillin resistance among VGS has remained
stable over time. During the 1990s, the appearance of penicil-
lin-resistant and highly resistant VGS strains accompanied the
emergence of infections caused by these microorganisms in
patients with cancer [8]. Most infections caused by these
strains have occurred under the selective pressure exerted by
b-lactam therapy. Furthermore, previous administration of b-
lactam antibiotics was found to be the major risk factor for
penicillin-resistant VGS bacteraemia in patients with cancer [8].
Current guidelines recommend the use of an antipseudo-
monal b-lactam (occasionally combined with another antibi-
otic), for the treatment of febrile episodes in neutropenic
patients with cancer [18]. Penicillin resistance among VGS
does not seem to be a clinical problem at present, but as the
consumption of antibiotics is increasing worldwide, it is rea-
sonable to think that it could become a matter of concern.
Among the GNB isolated in the second period, we
observed an increase in Enterobacteriaceae (other than E. coli)
especially Klebsiella spp. The most notable ﬁnding was the sig-
niﬁcant increase in multidrug-resistant GNB in the second per-
iod. This ﬁnding is consistent with those of recent studies,
which report an increase in antibiotic resistance among GNB
in immunocompetent and immunocompromised hosts, includ-
ing patients with malignancies and haematopoietic stem cell
transplant recipients [29–33]. In our study, ESBL-E. coli was
the most frequently isolated resistant microorganism in the
second period. In recent years, ESBL-E. coli has dramatically
increased as a cause of BSI throughout most of the world [30].
In a recent study, we also observed that ESBL-E. coli was the
most frequent resistant microorganism among a prospective
cohort of BSI occurring in cancer patients [33].
Overall case-fatality rate was similar in the two groups,
ranging from 15% to 19%. This ﬁnding is consistent with
other reports involving neutropenic patients with haemato-
logical malignancies [34,35]. Although early case-fatality rate
was higher in the second period, the difference did not
reach statistical signiﬁcance, probably because of the higher
frequency of gram-negative BSI in this period, and the
higher rate of antimicrobial resistance among the GNB.
Gram-negative BSI has been associated with higher mortal-
ity, and the risk is further increased if appropriate antibiotic
treatment is delayed because of antimicrobial resistance
[33,34,36]. However, several factors may inﬂuence out-
comes in patients with BSI, such as the underlying condi-
tion, severity of illness and primary site of infection [36].
To analyse the factors inﬂuencing mortality in neutropenic
patients with haematological malignancies was not an objec-
tive of our study.
Admission to the intensive care unit and mechanical venti-
lation were also more frequent in the second period. These
ﬁndings may also be attributed to the higher rate of gram-
negative BSI, which is usually associated with severe sepsis
and septic shock [36] and the recent trend to treat patients
more aggressively than in previous periods.
In conclusion, we found that the aetiology of BSI in neu-
tropenic patients with cancer has shifted from gram-positive
to gram-negative organisms. This is probably the result of dif-
ferences in the management of these patients in recent years,
which has led to a decrease in VGS and an increase in GNB.
The overall case-fatality rate in neutropenic patients with can-
cer with BSI remains high. The development of multidrug
resistance among GNB is emerging as a signiﬁcant therapeutic
problem. As antibiotic therapy options for multidrug-resistant
strains are limited, management of these serious infections in
these high-risk patients is becoming a clinical challenge.
Funding
This study was supported by research grant REIPI RD06/
0008 from the Ministerio de Sanidad y Consumo, Instituto
de Salud Carlos III, Spanish Network for the Research in
Infectious Diseases. M Bodro is the recipient of a research
grant from the Institut d’Investigacio´ Biome`dica de Bellvitge
(IDIBELL), Barcelona, Spain.
The funding sources had no role in the study design, the
collection, analysis and interpretation of the data or the deci-
sion to submit the manuscript for publication. Only the
authors had full access to the data ﬁles for the study.
Transparency Declarations
The authors do not have any relationship that may constitute
a dual or conﬂicting interest.
References
1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relation-
ship between circulating leukocytes and infection in patients with
acute leukaemia. Ann Intern Med 1966; 64: 328–340.
2. Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia com-
plicating neoplastic disease. Am J Med 1977; 62: 731–742.
478 Clinical Microbiology and Infection, Volume 19 Number 5, May 2013 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 474–479
3. Zinner SH. Changing epidemiology of infections in patients with neu-
tropenia and cancer: emphasis on gram-positive and resistant bacte-
ria. Clin Infect Dis 1999; 29: 490–494.
4. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends
in the epidemiology of nosocomial bloodstream infections in patients
with haematological malignancies and solid neoplasms in hospitals in
the United States. Clin Infect Dis 2003; 36: 1103–1110.
5. Ramphal R. Changes in the etiology of bacteremia in febrile neu-
tropenic patients and the susceptibilities of the currently isolated
pathogens. Clin Infect Dis 2004; 39 (suppl 1): S25–S31.
6. Marron A, Carratala` J, Gonza´lez-Barca E, Ferna´ndez-Sevilla A, Alcalde
F, Gudiol F. Serious complications of bacteremia caused by viridans
streptococci in neutropenic patients with cancer. Clin Infect Dis 2000;
31: 1126–1130.
7. Cometta A, Zinner S, de Bock R et al. Piperacillin-tazobacteam plus
amikacin versus ceftazidime plus amikacin as empiric therapy for
fever in granulocytopenic patients with cancer. The International
Antimicrobial Therapy Cooperative Group of the European Organi-
zation for research and treatment of cancer. Antimicrob Agents Chemo-
ther 1995; 39: 445–452.
8. Carratala` J, Alcaide F, Ferna´ndez-Sevilla A, Corbella X, Linares J, Gu-
diol F. Bacteremia due to viridans streptococci that are highly resis-
tant to penicillin: increase among neutropenic patients with cancer.
Clin Infect Dis 1995; 20: 1169–1173.
9. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due
to viridans streptococci: a case–control study of predisposing factors.
Clin Infect Dis 1992; 14: 1201–1207.
10. Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk fac-
tors for gram-positive coccal infections in neutropenia: toward a
more targeted antibiotic strategy. Clin Infect Dis 2003; 36: 149–158.
11. Gonza´lez-Barca E, Ferna´ndez-Sevilla A, Carratala` J, Gran˜ena A, Gudi-
ol F. Prospective study of 288 episodes of bacteremia in neutropenic
cancer patients in a single institution. Eur J Clin Microbiol Infect Dis
1996; 15: 291–296.
12. Clinical and Laboratory Standards Institute (Formely NCCLS). Perfor-
mance standards for antimicrobial susceptibility testing; twenty-ﬁrst infor-
mational supplement. CLSI document M100-S21 Vol 31 No. 1 [ISBN
1-56238-588-7]. Clinical and Laboratory Standards Institute, Wayne,
Pennsylvania, USA, 2011.
13. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of deﬁnitions of
multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter
baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55:
1619–29.
14. Murray PR, Baron EJ, Jorgersen JH, Landry ML, Pfaller MA (eds).
Manual of clinical microbiology, 9th edn. American Society of Microbiol-
ogy, Washington, DC, 2007.
15. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution
antimicrobial susceptibility test for bacteria that grow aerobically; Approved
Standard-Eight Edition. CLSI document M07-A8 Vol 29 No 2 [ISBN 1-
56238-607-7]. Clinical and Laboratory Standards Institute, Wayne,
PA, USA, 2009.
16. Clinical and Laboratory Standards Institute (CLSI). Performance stan-
dards for antimicrobial disk susceptibility test; approved standard-tenth edi-
tion. CLSI document M02-A10 (ISBN 1-56238-688-3). Clinical and
Laboratory Standards Institute, Wayne, PA, USA, 2009.
17. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quionolone pro-
phylaxis in afebrile neutropenic patients on microbial resistance: system-
atic review and meta-analysis. J Antimicrob Chemother 2007; 59: 5–22.
18. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guidelines
for the use of antimicrobial agents in neutropenic patients with can-
cer: 2010 update by the Infectious Diseases Society of America. Clin
Infect Dis 2011; 52: e56–e93.
19. Carratala` J, Ferna´ndez-Sevilla A, Tubau F, Dominguez MA, Gudiol F.
Emergence of ﬂuoroquinolone-resistant Escherichia coli in fecal ﬂora
of cancer patients receiving norﬂoxacin prophylaxis. Antimicrob Agents
Chemother 1996; 40: 503–505.
20. Carratala` J, Ferna´ndez-Sevilla A, Tubau F, Callis M, Gudiol F. Emer-
gence of quinolone-resistant Escherichia coli bacteremia in neutropenic
patients with cancer who have received prophylactic norﬂoxacin. Clin
Infect Dis 1995; 20: 557–560.
21. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant
to ﬂuoroquinolones in patients with cancer and neutropenia. N Engl J
Med 1994; 330: 1240–1241.
22. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emer-
gence of ﬂuoroquinolone-resistant Escherichia coli at a cancer center.
Antimicrob Agents Chemother 1994; 38: 681–687.
23. Asensio A, Alvarez-Espejo T, Ferna´ndez-Crehuet J et al. Trends in
yearly prevalence of third-generation and ﬂuoroquionolone resistant
Enterobacteriaceae infections and antimicrobial use in Spanish hospi-
tals, Spain, 1999 to 2010. Euro Surveill 2011; 16: pii:19983.
24. Rodrı´guez-Ban˜o J, Navarro MD, Romero L et al. Epidemiology and
clinical features of infections caused by extended-spectrum beta-lac-
tamase-producing Escherichia coli in nonhospitalized patients. J Clin
Microbiol 2004; 42: 1089–1094.
25. LeBlanc L, Pe´pin J, Toulouse K et al. Fluoroquinolones and risk for
methicillin-resistant Staphyloccocus aureus, Canada. Emerg Infect Dis
2006; 12: 1398–1405.
26. Pe´pin J, Saheb N, Coulombe MA et al. Emergence of ﬂuoroquinol-
ones as the predominant risk factor for Clostridium difﬁcile-associated
diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis
2005; 41: 1254–1260.
27. Winston DJ, Dudnik DV, Chapin M, Ho WG, Gale RP, Martin WJ.
Coagulase-negative staphylococcal bacteremia in patients receiving
immunosuppressive therapy. Arch Intern Med 1983; 143: 32–36.
28. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghaﬁ L, Francioli P.
Bacteremia due to viridans streptococcus in neutropenic patients with
cancer: clinical spectrum and risk factors. Clin Infect Dis 1994; 18: 25–31.
29. Oliveira AL, Souza M, Carvalho-Dias VM et al. Epidemiology of bac-
teremia and factors associated with multi-drug-resistant Gram-nega-
tive bacteremia in hematopoietic stem cell transplant recipients. Bone
Marrow Transplant 2007; 39: 775–781.
30. Rodrı´guez-Ban˜o J, Navarro MD, Romero L et al. Bacteremia due to
extended-spectrum b-lactamase-producing Escherichia coli in the
CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407–
1414.
31. Jacobson K, Rolston K, Elting L, LeBlanc M, Whimbey E, Ho DH. Sus-
ceptibility surveillance among gram-negative bacilli at a cancer center.
Chemotherapy 1999; 45: 325–334.
32. Krcme´ry V Jr, Spanik S, Krupova I et al. Bacteraemia due to multi-
resistant gram-negative bacilli in neutropenic cancer patients: a case-
controlled study. J Chemother 1998; 10: 320–325.
33. Gudiol C, Tubau F, Calatayud L et al. Bacteraemia due to multidrug-
resistant gram-negative bacilli in cancer patients: risk factors, antibi-
otic therapy and outcomes. J Antimicrob Chemother 2011; 66: 657–
663.
34. Tumbarello M, Spanu T, Caira M et al. Factors associated with mor-
tality in bacteremic patients with hematologic malignancies. Diagn
Microbiol Infect Dis 2009; 64: 320–326.
35. Wisplinghoff H, Cornely OA, Moser S et al. Outcomes of nosocomial
bloodstream infections in adult neutropenic patients: a prospective
cohort and matched case–control study. Infect Control Hosp Epidemiol
2003; 24: 905–911.
36. Kang CI, Kim SH, Park WB et al. Bloodstream infections caused anti-
biotic resistant Gram-negative bacilli: risk factors for mortality and
impact of inappropriate initial antimicrobial therapy on outcome. Anti-
microb Agents Chemother 2005; 49: 760–766.
CMI Gudiol et al. Bacteraemia in neutropenic cancer patients 479
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, 474–479
